AB Science SA

AB Science announces the successful completion of a 2.55 million euros private placement

03 Aug 2025 22:58:35 By Nasdaq GlobeNewswire

AB Science receives regulatory approval from European countries to initiate third stage of Phase I/II study combining its molecule AB8939 with venetoclax for the treatment of AML

29 Jul 2025 22:45:48 By Nasdaq GlobeNewswire

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

23 Jul 2025 22:57:04 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a EUR 1.925 million private placement

07 Jul 2025 23:01:55 By Nasdaq GlobeNewswire

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

03 Jul 2025 23:01:23 By Nasdaq GlobeNewswire

AB Science provides an update on the renegotiation of loan repayment terms with its financial creditors

29 Jun 2025 23:03:29 By Nasdaq GlobeNewswire

AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease

22 Jun 2025 23:03:15 By Nasdaq GlobeNewswire

AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036

11 Jun 2025 22:59:17 By Nasdaq GlobeNewswire

AB Science announces EMA approval of Masivet shelf-life extension to 4 years

08 Jun 2025 23:01:20 By Nasdaq GlobeNewswire

AB Science announces the settlement delivery of its latest capital increase for €1.8 million

22 May 2025 22:52:26 By Nasdaq GlobeNewswire

AB Science announces the successful completion of a EUR 1.8 million private placement

19 May 2025 22:49:42 By Nasdaq GlobeNewswire

AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection

18 May 2025 22:51:54 By Nasdaq GlobeNewswire

AB Science today reports a new publication in the scientific journal PLOS One, showing promising neuroprotective effects of masitinib

14 May 2025 23:07:23 By Nasdaq GlobeNewswire

AB Science reports its revenues for the year 2024 and provides an update on its activities

11 May 2025 23:14:35 By Nasdaq GlobeNewswire

AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual Meeting

05 May 2025 09:03:42 By Nasdaq GlobeNewswire

AB Science will publish its 2024 annual financial report on May 9, 2025

01 May 2025 01:06:22 By Nasdaq GlobeNewswire

AB Science announces that EMA granted orphan drug status to AB8939 for the treatment of acute myeloid leukemia

23 Apr 2025 09:59:03 By Nasdaq GlobeNewswire

AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease

14 Apr 2025 09:02:30 By Nasdaq GlobeNewswire

AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch

03 Mar 2025 23:35:15 By Nasdaq GlobeNewswire

AB Science today provides an update on its masitinib platform

29 Jan 2025 10:03:14 By Nasdaq GlobeNewswire